COVID/SARS CoV2 Rapid Research Reports #1
June 16 - 17, 2020 Virtual
Registration Deadline: June 11 @ 4 pm EDT  CLOSED
Late Registration Deadline: June 15 @ 4 pm EDT  CLOSED
Late registrants may face a short delay in accessing COVID-R3-1 conference


Hung Fan, University of California Irvine
Stanley Perlman, University of Iowa
Susan Weiss, University of Pennsylvania Perelman School of Medicine
David Stewart, Cold Spring Harbor Laboratory

With over 5.6 million cases of COVID, more than 350,000 deaths, and economic devastation on a global scale, the world scientific community will come together for a series of virtual meetings starting on June 16th. This monthly series will bring together expert scientists on the forefront of COVID research into viral origins & variation, virus biology, host response, and antivirals & vaccines. It is designed to stimulate ideas and collaborations among scientists with the goal of hastening a solution to vanquish this worldwide disease.

COVID-R3-#1 Invited Talks only June 16 - 17, 2020
COVID-R3 #2 Invited Talks only July 21 - 22, 2020
COVID-R3 #3 Invited & Selected Talks/Posters August 25 - 26, 2020

Covid R3 #1 Sessions and Discussion Leaders

Session I: Origins/Evolution, Molecular Biology I (Tuesday June 16: 9:30am EDT / 1:30pm UTC)
Co-Chairs: Kay Holmes & Stanley Perlman

Coronavirus Overview:  Susan Weiss - Coronaviruses: History and Biology

Linfa Wang, University of Singapore – Why bats?
Leo Poon, The University of Hong Kong - Bat origins
Tony Schountz, Colorado State University - SARS-CoV-2 Infection and Transmission in Deer Mice
Pedro Beltrao, European Bioinformatics Institute - The Global Phosphorylation Landscape of SARS-CoV-2 Infection
Ye Xiang, Tsinghua University – Entry of the SARS coronavirus and structure based vaccine development for SARS CoV2

Session II:  Molecular Biology II (Tuesday June 16: 2:00pm EDT / 6:00pm UTC)
Co-Chairs: Julian Leibowitz & Hung Fan

Jason McLellan, UT Austin/Andrew Ward, Scripps – Structure and Design of SARS-CoV-2 Spikes
David Veesler, University of Washington - SARS-CoV-2 spike-mediated entry into host cells and antibody neutralization
Eva Böttcher-Friebertshäuser, The Philipps University of Marburg - TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway cells
Stefan Pohlmann, The University of Göttingen - Proteolytic activation of SARS-CoV-2 and its inhibition
Roland Eils, Charité – Universitätsmedizin Berlin - Cross-talk between the airway epithelium and activated immune cells defines severity in COVID-19
Raoul de Groot, Utrecht University - Touch and go; coronavirus attachment to glycan-based receptors
Nevan Krogan, University of California-San Francisco – A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Session III:  Pathogenesis & Host Response (Wednesday June 17: 9:30am EDT / 1:30pm UTC)
Co-Chairs: Brenda Hogue & Tom Gallagher

Coronavirus Immunology Overview:  Stanley Perlman - Overview of immune responses in Coronavirus Infections

Jincun Zhao, Guangzhou – Kinetics of viral load and antibody response in relation to COVID-19 severity
Kwok-Yung Yuen, University of Hong Kong – Hamster model for COVID-19
Vincent Munster, NIH-RML - Medical countermeasure development against COVID19 in the rhesus macaques model
Tanya Miura, University of Idaho - MHV-1: A murine coronavirus model of pathogenesis in the respiratory tract
Bart Haagmans, Erasmus University Rotterdam – Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model 
Ralph Baric, University of North Carolina – Mouse Models for SARS Virus Pathogenesis and Vaccines

Session IV:  Antivirals & Vaccines (Wednesday June 17: 2:00pm EDT / 6:00pm UTC)
Co-Chairs: Susan Weiss & Mike Buchmeier

Danielle Porter, Gilead Sciences, Inc. – Overview of Remdesivir Development
Mark Denison, Vanderbilt University - Developing antivirals for SARS-CoV-2 and future zoonotic CoVs
Matthew Hall, NIH-NCATS - Drug Repurposing for COVID-19 and the NCATS OpenData Portal
Matt Frieman, University of Maryland - SARS-CoV-2 Therapeutic Development
George Yancopolous, Regeneron – Parallel High-Throughput Efforts, Using Both Humanized Mice and Convalescent Humans, Yields SARS-CoV-2 Antibody Cocktail that Prevents Rapid Mutational Escape Seen with Individual Antibodies
Andrea Carfi, Moderna - Rapid development of mRNA-1273: a vaccine against SARS-CoV-2
David Wiener, University of Pennsylvania - Synthetic DNA Vaccination for SARS-CoV2
Luis Enjuanes, Universidad Autonoma de Madrid – Vaccines for deadly human coronaviruses based on replication-competent propagation-deficinent RNA replicons

Virtual 2 day live meeting + archive access

Card image cap
~32 talks / 4 sessions
(late am/early pm)
~12 total hours with interactive Q&A
Card image cap
Leading Strand video archive access to talks
Card image cap
Twitter for meeting news & general comments

Standard Rate (single conference registration)
$129 - Register after June 11 @ 4:01 pm EDT - registration closes June 15 @ 4:00 pm EDT

Combo Virtual Package (COVID-R3 #1, #2 and #3 conferences): $250
(Combo Registrants may extend enrollment for future COVID-R3 conferences for $75/conference)

Lab Group Discounts (10+ Participants):
Standard Registration (Single Conference Registration): 
Labs registering 10-25 people: 35% discount
Labs registering 25+ people: 40% discount
Combo Virtual Package (COVID-R3 #1, #2 and #3 conferences):
Labs registering 10-25 people: 35% discount
Labs registering 25+ people: 40% discount
To be eligible for lab group discounts, please submit a list of lab members planning to attend in advance of registration to Alicia Franco & Shannon Silva to establish appropriate discounted fees. Please include a link to your lab webpage for verification purposes. Prior payments will be included in the group discount calculation.

Virtual Attendance packages include access to online Zoom-based oral sessions with live Q&A and access to the video archive on the Leading Strand for ~twelve weeks following each meeting.